HER2-positive breast cancer

Latest news

Tag

Targeting the PI3K/AKT Pathway: Ipatasertib Shows Promise as Maintenance Therapy for PIK3CA-Mutated, HER2-Positive Metastatic Breast Cancer

The Phase 1b SOLTI-1507 IPATHER trial demonstrates that adding the AKT inhibitor ipatasertib to trastuzumab and pertuzumab is a safe and clinically active maintenance strategy for patients with PIK3CA-mutated HER2-positive metastatic breast

Jan 13, 2026

news

Trastuzumab Deruxtecan Plus Pertuzumab: A Promising First-Line Therapy for HER2-Positive Metastatic Breast Cancer

Trastuzumab deruxtecan combined with pertuzumab significantly improves progression-free survival over standard therapy in first-line HER2-positive metastatic breast cancer, offering enhanced response duration with manageable safety.

Oct 31, 2025

Internal Medicine

Real-World Insights into HER2-Positive Metastatic Breast Cancer Treatments: Comparing T-DXd, T-DM1, and Tucatinib

This study uses real-world data to compare the effectiveness and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib in HER2-positive metastatic breast cancer, confirming their clinical value.

Oct 18, 2025Sign in to read